Mounjaro outperforms Ozempic in both weight loss and blood sugar control, based on the only head-to-head clinical trial comparing the two. In the SURPASS-2 trial, people taking Mounjaro’s highest dose lost nearly twice as much body weight as those on Ozempic over 40 weeks. The difference comes down to how each drug works: Mounjaro targets two gut hormones instead of one, giving it a broader effect on appetite, blood sugar, and metabolism.
How the Two Drugs Actually Work
Ozempic (semaglutide) mimics a single gut hormone called GLP-1, which your body naturally releases after eating. This hormone signals your brain to feel full, slows digestion, and helps your pancreas release insulin at the right time. It’s effective, but it only pulls one lever.
Mounjaro (tirzepatide) mimics that same GLP-1 hormone plus a second one called GIP. Together, these two hormones appear to have a compounding effect on appetite suppression, insulin sensitivity, and how your body processes fat. This dual-action mechanism is the core reason Mounjaro consistently produces stronger results in clinical trials.
Weight Loss: The Head-to-Head Numbers
The SURPASS-2 trial is the gold standard comparison because it tested Mounjaro directly against Ozempic in the same study population: adults with type 2 diabetes, all taking metformin as a baseline treatment. After 40 weeks, the results were clear across every Mounjaro dose level.
People on Ozempic (1 mg) lost an average of 6.2 kg, or about 6.7% of their body weight. Mounjaro users lost significantly more at every dose: 7.8 kg (8.5%) on the 5 mg dose, 10.3 kg (11.0%) on 10 mg, and 12.4 kg (13.1%) on 15 mg. At the highest dose, that’s roughly double the weight loss of Ozempic in the same timeframe.
It’s worth noting that this trial used Ozempic at 1 mg, which was the standard maximum dose at the time. Ozempic now has a 2 mg dose option, which may narrow the gap somewhat, though no head-to-head trial has tested that comparison yet.
Blood Sugar Control
Both medications were originally developed for type 2 diabetes, and both are effective at lowering A1C (the measure of average blood sugar over roughly three months). But Mounjaro again had an edge in SURPASS-2.
All groups started with an average A1C of 8.3%. After 40 weeks, Ozempic brought that down by 1.9 percentage points. Mounjaro reduced A1C by 2.0 points at 5 mg, 2.2 points at 10 mg, and 2.3 points at 15 mg. The differences may look small on paper, but in diabetes management, even a few tenths of a percentage point can meaningfully reduce the risk of complications over time. At the highest dose, Mounjaro delivered about 20% more A1C reduction than Ozempic.
FDA Approvals Are Different
Both drugs are FDA-approved for type 2 diabetes: Mounjaro (tirzepatide) and Ozempic (semaglutide) are both prescribed alongside diet and exercise to improve blood sugar control. But for weight loss specifically, neither brand is technically approved under those names.
Each drug has a separate brand name for weight management. Semaglutide is sold as Wegovy for weight loss. Tirzepatide is sold as Zepbound. Zepbound is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. The active ingredients are identical to their diabetes counterparts, but the branding, dosing, and insurance coverage differ. If your primary goal is weight loss rather than diabetes management, your prescription will likely be written for Zepbound or Wegovy rather than Mounjaro or Ozempic.
Dosing and Titration Schedule
Both medications are once-weekly injections given under the skin, typically in the stomach, thigh, or upper arm. Both start at a low dose and gradually increase to reduce side effects, but the timelines differ slightly.
Mounjaro starts at 2.5 mg weekly, then moves to 5 mg after four weeks. From there, your doctor can increase the dose in 2.5 mg steps up to a maximum of 15 mg, depending on how you respond and what you can tolerate. Ozempic starts lower at 0.25 mg weekly, with a maximum of 2 mg. The slower start with both drugs is designed to let your digestive system adjust, since nausea is the most common early side effect for both medications.
Side Effects Are Similar
Because both drugs work through overlapping pathways, they share most of the same side effects. Nausea, vomiting, diarrhea, decreased appetite, and constipation are the most frequently reported issues with both Mounjaro and Ozempic. These tend to be worst during dose increases and often improve after a few weeks at a stable dose.
Some data suggests that gastrointestinal side effects may be slightly more common with Mounjaro at higher doses, which makes sense given its stronger overall effect. However, the rates of people discontinuing treatment due to side effects were similar between the two drugs in clinical trials. For most people, the side effects are manageable and temporary.
Cost and Availability
Neither medication is cheap. Mounjaro’s list price is $1,112.16 for a one-month supply (four pens). Ozempic’s list price is in a similar range. What you actually pay depends heavily on your insurance plan, any manufacturer savings programs, and whether you’re prescribed the diabetes or weight loss version of the drug. Insurance coverage for weight loss medications remains inconsistent, and many plans cover the diabetes indication more readily.
Supply has been a practical concern for both drugs over the past two years, as demand surged well beyond initial manufacturing capacity. As of early 2025, neither tirzepatide nor semaglutide appears on the FDA’s drug shortage list, suggesting that supply has largely stabilized. That said, specific dose strengths can still be harder to find at individual pharmacies, so availability may vary by location.
So Is Mounjaro Actually “Better”?
By the numbers, Mounjaro produces more weight loss and slightly better blood sugar control than Ozempic at the doses tested head-to-head. The dual-hormone mechanism gives it a pharmacological advantage that shows up consistently in trial data. For someone whose primary goal is maximizing weight loss or achieving the tightest possible blood sugar control, the clinical evidence favors Mounjaro.
That said, “better” depends on your situation. Ozempic has a longer track record, with more years of real-world safety data. Some people respond well to one drug but not the other. Insurance coverage, out-of-pocket cost, and which medication your pharmacy can actually stock all play a role. Both drugs represent a significant advance over older options, and both produce meaningful results for most people who take them. The gap between them is real but not enormous, particularly at Mounjaro’s lower doses compared to Ozempic’s higher ones.